More than half Canada's AstraZeneca vaccine came from U.S. plant accused by FDA of quality-control problemsControversy first erupted in March when it was revealed that cross-contamination at the Baltimore plant had ruined 15 million doses of the J&J product
Author of the article:
Apr 23, 2021 • Last Updated 23 minutes ago • 4 minute read
Close to two thirds of the AstraZeneca COVID-19 vaccine imported into Canada came from a U.S. factory that American authorities say was rife with quality-control issues, Health Canada confirmed Thursday.
The U.S. Food and Drug Administration said this week it will not allow the release of any vaccine made under contract at the Emergent Biosolutions plant in Baltimore, Md. — and still in the U.S.— until it’s been tested further.